Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

Shelley Wood

April 06, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

Shelley Wood

April 02, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Grants Stroke Prevention Indication to Ticagrelor

Shelley Wood

November 06, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

Todd Neale

October 14, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

Advertisement

FDA Approves Triple Therapy Polypill for High Blood Pressure

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

Bempedoic Acid Gains CV Risk Reduction Indication

TCTMD’s Top 10 Most Popular Stories for December 2023

FDA Approves Colchicine for Decreasing CV Events

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

British Medical Groups Express Concern About Inclisiran Rollout

Xience Cleared in Europe for 1-Month DAPT in High-Bleeding-Risk Patients

TCTMD’s Top 10 Most Popular Stories for March 2021

Roughly 80% of ESC Guideline Writers Have Financial COIs

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Grants Stroke Prevention Indication to Ticagrelor

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Approves Two Generic Versions of Apixaban

FDA Gives Rivaroxaban Another VTE-Related Indication

TCTMD’s Top 10 Most Popular Stories for August 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content